CSL Limited (CMXHF)
| Previous close | 184.00 |
| Open | 183.75 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 183.75 - 183.75 |
| 52-week range | 173.20 - 234.00 |
| Volume | |
| Avg. volume | 555 |
| Market cap | 89.451B |
| Beta (5Y monthly) | 0.10 |
| PE ratio (TTM) | 36.17 |
| EPS (TTM) | 5.08 |
| Earnings date | N/A |
| Forward dividend & yield | 2.18 (1.19%) |
| Ex-dividend date | 07 Mar 2022 |
| 1y target est | N/A |
- Simply Wall St.
CSL Limited's (ASX:CSL) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
CSL (ASX:CSL) has had a rough month with its share price down 1.6%. However, stock prices are usually driven by a...
- PR Newswire
CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has included FLUAD® QUADRIVALENT as a preferentially recommended seasonal influenza vaccine for adults 65 years of age and older. The preferential recommendation for FLUAD QUADRIVALENT for all adults 65 years and older is based on the clinical benefits compared to standard egg
- PR Newswire
Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with Hemophilia
Global biotherapeutics leader CSL Behring and renowned portrait photographer Rankin have teamed up to launch 'Portraits of Progress', a multi-media campaign showcasing the stories and experiences of people living with hemophilia from the mid-twentieth century to today. This first-of-its-kind exhibition takes visitors through the remarkable pace of progress in the treatment of hemophilia, from the identification of hemophilia A and B in the 1940s, through treatment advances available today, and o
